Response to BV/Len treatment based on patient’s CD30 status (positive or negative) and DLBCL subtype by Hans’ criteria
| . | CD30 status/Hans’ criteria . | |||||||
|---|---|---|---|---|---|---|---|---|
| CD30+/GCB (n = 8) . | CD30−/GCB (n = 12) . | CD30+/non-GCB (n = 7) . | CD30−/non-GCB (n = 10) . | |||||
| Response . | n . | % . | n . | % . | n . | % . | n . | % . |
| CR | 4 | 50 | 2 | 17 | 2 | 29 | 5 | 50 |
| PR | 3 | 37.5 | 1 | 8 | 2 | 29 | 2 | 20 |
| SD | 1 | 12.5 | 4 | 33 | 0 | 0 | 0 | 0 |
| PD | 0 | 0 | 5 | 42 | 3 | 43 | 3 | 30 |
| ORR (CR+PR) | 7 | 87.5 | 3 | 25 | 4 | 57 | 7 | 70 |
| . | CD30 status/Hans’ criteria . | |||||||
|---|---|---|---|---|---|---|---|---|
| CD30+/GCB (n = 8) . | CD30−/GCB (n = 12) . | CD30+/non-GCB (n = 7) . | CD30−/non-GCB (n = 10) . | |||||
| Response . | n . | % . | n . | % . | n . | % . | n . | % . |
| CR | 4 | 50 | 2 | 17 | 2 | 29 | 5 | 50 |
| PR | 3 | 37.5 | 1 | 8 | 2 | 29 | 2 | 20 |
| SD | 1 | 12.5 | 4 | 33 | 0 | 0 | 0 | 0 |
| PD | 0 | 0 | 5 | 42 | 3 | 43 | 3 | 30 |
| ORR (CR+PR) | 7 | 87.5 | 3 | 25 | 4 | 57 | 7 | 70 |
PD, progressive disease; SD, stable disease.